ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-13

Price

$114.87

+0.03%

Score17.5Top Tier

Signals7/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

ACLX is trading flat at $114.87 because the stock is heavily pegged to Gilead's definitive $115-per-share cash acquisition offer. The technical signals (SURGE, ALPHA_MALE) reflect the massive structural gap-up from the February buyout announcement, while the QUIET_STORM signal and 1.9% realized volatility perfectly capture the current merger arbitrage consolidation. Although the broader equities market is enjoying a strong RISK_ON regime fueled by geopolitical tailwinds, ACLX's price action is entirely insulated and driven by deal mechanics. High conviction is warranted as the market prices in a near-certain Q2 2026 close, with marginal upside tied to a $5 Contingent Value Right (CVR).

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

The stock is strictly trading as a merger arbitrage vehicle, pinned just below Gilead's $115/share cash offer.
A $5 Contingent Value Right (CVR) provides additional upside optionality if anito-cel hits $6B in cumulative sales by 2029, keeping the price structurally supported.
Key risk is regulatory antitrust scrutiny or deal collapse, though Gilead's existing 11.5% stake and prior development partnership make this a low-probability event.

← Back to 2026-04-13 View Full ACLX History →Yahoo Finance &nearr;